My grandmother was diagnosed with Parkinson’s disease at 71. I watched her hands shake at the dinner table long before anyone gave it a name. That personal history is part of why I’ve spent the last several years following the science of neurodegeneration closely — and why what’s emerging around brain inflammation genuinely excites me.
For most of my adult life, the explanation I heard for Parkinson’s was simple: the cells that make dopamine in a region of the brain called the substantia nigra gradually die, and without dopamine, the brain can’t coordinate movement properly. Tremors, rigidity, slow movement — all of it traces back to that one loss.
That explanation is true. But it may be dangerously incomplete. Because it doesn’t answer the more important question: why are those cells dying in the first place?
A new body of research suggests the answer has less to do with dopamine itself and more to do with something that starts much earlier — chronic inflammation quietly burning through the brain, years before a single symptom appears.
What “neuroinflammation” actually means
Inflammation is the body’s repair system. When something goes wrong — an injury, an infection, a chemical imbalance — the immune system activates, sends in molecular signals, tries to fix the damage, and then ideally switches off. That last part is key. Switches off.
In many people with Parkinson’s disease, researchers are finding that the inflammatory response doesn’t fully switch off. Microglia, the brain’s resident immune cells, stay in a state of low-grade activation. Pro-inflammatory cytokines — particularly one called TNF-alpha — remain elevated in brain tissue long after they should have subsided.
That persistent TNF-alpha elevation sets off a chain of events that researchers are only now mapping in detail. It blocks a protein called IRS-1, which is essential for neurons to process insulin correctly. Without that insulin signaling, dopamine-producing neurons can’t access energy efficiently. Their mitochondria weaken. They become fragile. And over time, they die.
“We’ve been treating Parkinson’s like a dopamine problem for fifty years. What if it’s actually an inflammation problem that happens to destroy dopamine neurons?”
Two molecular pathways sit at the center of this process: ERK, which regulates how cells respond to signals from outside, and NFκB, a master switch for inflammatory gene expression. When chronic inflammation keeps both of these pathways dysregulated over years and decades, the cumulative damage to dopamine neurons may be what ultimately tips into Parkinson’s disease.
Why this changes everything about treatment
Here’s the thing about levodopa, the drug that has been the cornerstone of Parkinson’s treatment since the 1960s: it works remarkably well — for a while. It replenishes dopamine, eases symptoms, and genuinely improves quality of life for millions of patients.
But it does absolutely nothing about the inflammation. The neurons keep dying. The disease keeps progressing. Doses have to increase, side effects accumulate, and eventually the drug that once felt like a miracle starts to feel like a losing battle.
If inflammation is truly upstream of dopamine neuron loss — not a side effect of it, but a cause — then the most important treatment isn’t one that replaces dopamine after neurons are already gone. It’s one that protects neurons before they die. That’s a fundamentally different goal, and it requires a fundamentally different drug.
What the clinical research looks like right now
I want to be careful here, because this is where science reporting can easily tip into false hope. So let me be precise: the neuroinflammation hypothesis for Parkinson’s is well-supported by preclinical and early clinical data, but it has not yet been proven in a large, definitive trial. That work is ongoing.
The most advanced clinical program I’ve been following that specifically targets this pathway is being run by a company called BioVie (NASDAQ: BIVI), using an investigational oral drug called bezisterim (NE3107). What caught my attention about bezisterim is how specifically it’s designed: it modulates ERK and NFκB — the two inflammatory pathways I described earlier — without broadly suppressing the immune system. That selectivity matters a great deal in older patients, where immune suppression carries real risks.
BioVie has already completed an earlier Phase 2 study in moderate-to-severe Parkinson’s patients. People taking bezisterim alongside levodopa showed better motor control and reported fewer troublesome morning symptoms compared to those taking levodopa alone. Side effects were minimal. That’s encouraging, though early-phase data always needs to be interpreted with caution.
The current trial, called SUNRISE-PD, is more ambitious. It’s studying bezisterim as a standalone treatment — no levodopa — in patients who are earlier in their disease course and haven’t yet started carbidopa/levodopa therapy. The logic is straightforward: if bezisterim can reduce neuroinflammation and protect dopamine neurons before significant loss has occurred, the impact could be far greater than anything achievable later in the disease. Topline data from this trial is expected in Q3 2026.
More information on BioVie’s Parkinson’s program can be found at bioviepharma.com/parkinsons.
What I think is worth watching
I’ve been covering clinical-stage science long enough to know that most trials fail, and that promising mechanisms don’t always translate into effective drugs. The history of Alzheimer’s research, in particular, is a graveyard of once-exciting hypotheses. I’m not forecasting that SUNRISE-PD will succeed.
But I do think the neuroinflammation angle for Parkinson’s deserves serious attention, for a few reasons. First, the mechanism is more specific than previous attempts — targeting defined molecular pathways rather than broadly dampening inflammation. Second, bezisterim has already shown a signal in human patients, not just in mice. Third, the trial design targets early-stage disease, which is where disease-modifying therapy would matter most.
Ten million people worldwide are living with Parkinson’s disease today. There is no approved therapy that slows its progression. If the data readouts in the second half of 2026 are positive, it would represent one of the more meaningful advances in Parkinson’s research in decades.
That’s worth paying attention to. Not with breathless optimism, but with clear eyes and genuine curiosity — which, in my experience, is exactly the right posture for following science at the edge of what we know.
About Author
Emily Parker is an independent science and health writer specializing in neurology, neurodegeneration, and clinical-stage biotechnology. She covers emerging research at the intersection of brain inflammation, metabolic disease, and drug development. She writes independently and has no financial affiliation with any company mentioned in her articles. For editorial inquiries, contact via the publication’s desk.
